para-Cymene, more commonly written as p-cymene, is a widespread aromatic monoterpene hydrocarbon found in many herb, spice, and resin oils. The strongest evidence supports its identity, broad occurrence in thyme-, oregano-, cumin-, and related chemotypes, plus a sizable preclinical literature on inflammatory signaling and antimicrobial-adjacent effects. Human clinical evidence for isolated para-cymene is still limited, and a modern fragrance-safety assessment exists, so the safest archive framing is chemistry-first with carefully labeled preclinical mechanisms and restrained consumer copy.
Chemical identity and composition
PubChem identifies p-cymene as CID 7463 with formula C10H14 and IUPAC name 1-methyl-4-propan-2-ylbenzene. ChEBI describes it as a monoterpene and volatile oil component with roles as a plant metabolite and human urinary metabolite. In the archive it appears repeatedly across phenolic herb profiles and mixed monoterpene oils, including oregano at 12.97%, thyme ct. thymol at 23.5%, pink pepper at 4.44%, and eucalyptus globulus at 4.15%, which makes it one of the better-supported occurrence markers in the database.
Aroma and practical use
- Use the recorded terpenic, solvent-like, citrus-peel, mildly woody descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
In the archive, para-cymene is repeatedly quantified as a meaningful essential-oil constituent, including 12.97% in oregano, 23.5% in thyme ct. thymol, 4.44% in pink pepper, and 4.15% in eucalyptus globulus.
In the archive, para-cymene is repeatedly quantified as a meaningful essential-oil constituent, including 12.97% in oregano, 23.5% in thyme ct. thymol, 4.44% in pink pepper, and 4.15% in eucalyptus globulus.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
A 2013 study reported that p-cymene modulated cytokine production in vitro and in vivo by downregulating TNF-alpha, IL-1beta, and IL-6 and by inhibiting MAPK and NF-kB pathway activation.
A 2013 study reported that p-cymene modulated cytokine production in vitro and in vivo by downregulating TNF-alpha, IL-1beta, and IL-6 and by inhibiting MAPK and NF-kB pathway activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2014 mouse study found that p-cymene attenuated LPS-induced acute lung injury, decreased inflammatory-cell numbers in BALF, reduced NF-kB protein levels in lungs, and improved oxidative-stress markers.
A 2014 mouse study found that p-cymene attenuated LPS-induced acute lung injury, decreased inflammatory-cell numbers in BALF, reduced NF-kB protein levels in lungs, and improved oxidative-stress markers.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2015 pharmacology paper reported that p-cymene reduced carrageenan-, TNF-alpha-, dopamine-, and PGE2-induced hyperalgesia, lowered leukocyte migration and TNF-alpha, and showed opioid-system involvement in tail-flick testing.
A 2015 pharmacology paper reported that p-cymene reduced carrageenan-, TNF-alpha-, dopamine-, and PGE2-induced hyperalgesia, lowered leukocyte migration and TNF-alpha, and showed opioid-system involvement in tail-flick testing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2016 mouse emphysema model found that p-cymene, carvacrol, and thymol all reduced alveolar enlargement, macrophages, inflammatory cytokines, collagen fibers, MMP-9, and p-65-NF-kB-positive cells in lung tissue.
A 2016 mouse emphysema model found that p-cymene, carvacrol, and thymol all reduced alveolar enlargement, macrophages, inflammatory cytokines, collagen fibers, MMP-9, and p-65-NF-kB-positive cells in lung tissue.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 1996 inhalation-toxicity study in rats reported exposure-related changes in synaptosomal neurochemistry after four weeks of p-cymene inhalation, showing that isolated-solvent-style exposure can affect neurochemical endpoints even though persistent regional neurotransmitter changes were not seen.
A 1996 inhalation-toxicity study in rats reported exposure-related changes in synaptosomal neurochemistry after four weeks of p-cymene inhalation, showing that isolated-solvent-style exposure can affect neurochemical endpoints even though persistent regional neurotransmitter changes were not seen.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
A 2021 RIFM fragrance ingredient safety assessment exists for p-cymene, making it a better-documented fragrance material than many minor terpenes, but the abstract alone does not publish a simple archive-ready numeric dermal limit.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
p-Cymene is consistently handled in chemical databases and supplier listings as a flammable volatile hydrocarbon, so storage and formulation should reflect solvent-like handling rather than fixed-oil assumptions.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The inhalation neurochemistry study in rats indicates that high or repeated isolated exposure is not safety-neutral, so strong wellness claims should not be paired with casual assumptions of unrestricted exposure.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
alpha-PineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read alpha-Pinene report →gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read gamma-Terpinene report →LinaloolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Linalool report →CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Carvacrol report →alpha-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · antioxidant
No source citation attached.
Read alpha-Terpinene report →ThymolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Thymol report →alpha-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read alpha-Terpinene report →CarvacrolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · whole_oil
No source citation attached.
Read Carvacrol report →LimoneneOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Limonene report →Terpinen-4-olOpposing candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Terpinen-4-ol report →alpha-TerpineolNeutral record
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read alpha-Terpineol report →CuminaldehydeAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · effect
No source citation attached.
Read Cuminaldehyde report →How the effects were investigated
nfkb and mapk inhibition
In LPS-stimulated cell and mouse models, p-cymene suppressed inflammatory cytokines while inhibiting I-kappaB-alpha, ERK1/2, p38, and JNK signaling, supporting NF-kB and MAPK pathway involvement.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
cytokine and no modulation
Mouse pharmacology work reported reductions in TNF-alpha, leukocyte migration, and nitric-oxide production, consistent with broader inflammatory mediator modulation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
lung inflammation marker reduction
In elastase- and LPS-based mouse lung models, p-cymene reduced inflammatory-cell burden, cytokines, and NF-kB-related readouts, indicating repeatable anti-inflammatory effects across different respiratory injury models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (8)
- The isolated-constituent literature is dominated by animal and cell models rather than human trials.
- A numeric constituent-specific IFRA dermal restriction level does not exist for p-cymene because the 2021 RIFM safety assessment concluded (via weight-of-evidence including a human maximization test at 4% and LLNA up to 30%) that it is not a skin sensitizer and does not require a use restriction; dermal_limit_pct therefore remains null by design, not by omission.
- Consumer-facing copy should avoid converting cytokine or lung-model findings into disease-treatment claims.
- Second-pass verification (2026-07-13) retrieved and read the full RIFM 2021 safety assessment PDF directly (prior pass only had the PubMed abstract). This confirmed sensitizing:false and phototoxic:false with citable full-text locators. penetration_enhancer remains unverified/null; no source addressing skin-penetration-enhancing effects of p-cymene was located.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.
- Some findings lack a directly linked source; treat those entries as unverified research notes.